Dutch
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
glaucoma/epileptische aanval
De link wordt op het klembord opgeslagen
Bladzijde 1 van 26 resultaten
Cyclohexylamine derivatives as subtype selective N-Methyl-D-Aspartate antagonists
Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
FIELD OF THE INVENTION
The invention provides cyclohexylamine derivatives as N-Methyl-D-Aspartate (NMDA) antagonists, pharmacological compositions comprising the derivatives, and methods of treating diseases and disorders responsive to antagonism of NMDA receptors using the derivatives.
BACKGROUND
Substituted 2,3-benzodiazepin-4-ones and the use thereof
Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
This application claims benefit of U.S. provisional application Ser. No. 60/013,813 filed Mar. 21, 1996.
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention is in the field of medicinal chemistry. In particular, the invention relates to novel substituted 2,3-benzodiazepin-4-ones.
4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists
Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention is related to 4-substituted piperidine analogs, including hydroxypiperidine and tetrahydropyridine analogs, as well as novel intermediates of the 4-substituted analogs. The analogs are selectively active as antagonists of
4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists
Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention is related to 4-substituted piperidine analogs, including hydroxypiperidine and tetrahydropyridine analogs, as well as novel intermediates of the 4-substituted analogs. The analogs are selectively active as antagonists of
2-substituted piperidine analogs and their use as subtype-selective NMDA receptor antagonists
Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention is related to 2-substituted piperidine analogs. The analogs are selectively active as antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes. The invention is also directed to the use of 2-substituted piperidine analogs as
2-substituted piperidine analogs and their use as subtype-selective NMDA receptor antagonists
Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention is related to 2-substituted piperidine analogs. The analogs are selectively active as antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes. The invention is also directed to the use of 2-substituted piperidine analogs as
4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists
Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention is related to 4-substituted piperidine analogs, including hydroxypiperidine and tetrahydropyridine analogs. The analogs are selectively active as antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes. The invention is also
Piperidine derivatives as subtype selective N-Methyl-D-Aspartate antagonists
Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
FIELD OF INVENTION
The invention relates to piperidine derivatives as N-Methyl-D-Aspartate (NMDA) antagonists useful in the treatment of diseases and disorders responsive to antagonism of NMDA receptors.
BACKGROUND OF THE INVENTION
Many of the physiological and pathophysiological effects of the
Compositions and methods for the suppression of carbonic anhydrase activity
Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
PRIORITY
This application is a national phase filing of the Patent Cooperation Treaty (PCT) application # PCT/IB2013/050899 titled "COMPOSITIONS AND METHODS FOR THE SUPPRESSION OF CARBONIC ANHYDRASE ACTIVITY" filed on Feb. 3, 2013 Published with WIPO Publication # WO/2013/167994, which further
Method and composition for treatment of ischemic neuronal reperfusion injury
Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
FIELD OF THE INVENTION
This invention relates to the treatment of neuropathy resulting from ischemic reperfusion injury in a mammal. Such neuropathies include, but are not limited to, optic ischemic neuropathy, stroke, reperfusion injury after TPA treatment or other lytic treatments/carotid
Imidazoline compounds
Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
TECHNICAL FIELD
The present invention is useful in medical fields. In more detail, novel imidazoline compounds of this invention are useful as neuropeptide Y receptor antagonists and as agents for the treatment of various kinds of cardiovascular disorders, central nervous system disorders, metabolic
Imidazonline compounds
Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
This application is a 371 of PCT/JP01/01312 filed Feb. 22, 2001.
TECHNICAL FIELD
The present invention is useful in medical fields. In more detail, novel imidazoline compounds of this invention are useful as neuropeptide Y receptor antagonists and as agents for the treatment of various kinds of
Compositions and methods for the treatment of moderate to severe pain
Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
PRIORITY
The present application claims the benefit of Indian Provisional Patent Application No. 1840/CHE/2012 filed on 10 May 2012 and the International Application No. PCT/IB2013/050924 filed on 4 Feb. 2013, the entire disclosure of which is relied on for all purposes and is incorporated into this
Adenosine receptor agonists, partial agonists, and antagonists
Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
BACKGROUND OF THE INVENTION
There are four subtypes of receptors for adenosine, designated A.sub.1, A.sub.2A, A.sub.2B, and A.sub.3. The A.sub.3 adenosine receptor is found primarily in the central nervous system, brain, testes, and the immune system, where it appears to be involved in the
Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
Alleen geregistreerde gebruikers kunnen artikelen vertalen
Log in Schrijf in
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a national phase of International Application No. PCT/US2014/027450 filed on Mar. 14, 2014, which claims the benefit of U.S. Provisional Application No. 61/785,478 filed on Mar. 14, 2013, each of which are incorporated herein by reference
De meest complete database met geneeskrachtige kruiden, ondersteund door de wetenschap
- Werkt in 55 talen
- Kruidengeneesmiddelen gesteund door de wetenschap
- Kruidenherkenning door beeld
- Interactieve GPS-kaart - tag kruiden op locatie (binnenkort beschikbaar)
- Lees wetenschappelijke publicaties met betrekking tot uw zoekopdracht
- Zoek medicinale kruiden op hun effecten
- Organiseer uw interesses en blijf op de hoogte van nieuwsonderzoek, klinische onderzoeken en patenten
Typ een symptoom of een ziekte en lees over kruiden die kunnen helpen, typ een kruid en zie ziekten en symptomen waartegen het wordt gebruikt.
* Alle informatie is gebaseerd op gepubliceerd wetenschappelijk onderzoek
